11 September, 2021 by The TZ Newswire Staff Comments Off on 3 Smartest Big Pharma Stocks to Buy in September
3 Smartest Big Pharma Stocks to Buy in September
Big pharma stocks appeal to many investors. Why? They often offer relative stability and solid (albeit not always spectacular) growth prospects. Many of these stocks also provide strong dividends.
We asked three Motley Fool contributors to pick the smartest big pharma stocks to buy in September. Here’s why they chose Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Teva Pharmaceutical (NYSE: TEVA).
Image source: Getty Images.
11 September, 2021 by The TZ Newswire Staff Comments Off on Why Eli Lilly’s COVID Antibody Therapy Is Making a Comeback
Why Eli Lilly’s COVID Antibody Therapy Is Making a Comeback
In June, the U.S. government halted the distribution of Eli Lilly‘s (NYSE: LLY) COVID-19 antibody cocktail. The problem was that the therapy didn’t seem to be effective against emerging coronavirus variants.
But now the U.S. is allowing Lilly’s antibody combo to be used once again in many states. In this Motley Fool Live video recorded on Sept. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Lilly’s COVID antibody therapy is making a comeback.
11 September, 2021 by The TZ Newswire Staff Comments Off on 3 Reasons a Roth IRA Is a Smart Home for Your Retirement Savings
3 Reasons a Roth IRA Is a Smart Home for Your Retirement Savings
The Roth IRA has been around for less than 25 years, but it has already become one of the most popular retirement accounts, especially among younger adults who haven’t yet hit the peaks of their careers.
It isn’t a great fit for everyone, but if any of the following benefits appeal to you, consider adding one to your retirement plan.
Image source: Getty Images.
11 September, 2021 by The TZ Newswire Staff Comments Off on Here’s Where Novavax May Beat Moderna and Pfizer
Here’s Where Novavax May Beat Moderna and Pfizer
Early in the coronavirus vaccine race, Novavax (NASDAQ: NVAX) seemed to have secured the third spot behind rivals Moderna (NASDAQ: MRNA) and Pfizer. The U.S. Food and Drug Administration (FDA) authorized the Moderna and Pfizer vaccines in December. And it looked like Novavax would submit its U.S. authorization request in the first half of this year.
But Novavax fell behind as materials shortages hurt its manufacturing ramp up. Now, the company expects to file for authorization in the fourth quarter.